In phase @ studies , treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS@A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus ( HCV ) genotype @ infection .